Avapritinib - Blueprint Medicines
Alternative Names: AYVAKIT; AYVAKYT; Ayvakyt; BLU-285; CS 3007; TaijihuaLatest Information Update: 11 Jun 2025
At a glance
- Originator Blueprint Medicines
- Developer Blueprint Medicines; CStone Pharmaceuticals; Neopharm Ltd
- Class 2 ring heterocyclic compounds; Amines; Antineoplastics; Pyrazoles; Pyrimidines; Pyrroles; Skin disorder therapies; Small molecules; Triazines
- Mechanism of Action Platelet-derived growth factor alpha receptor antagonists; Proto-oncogene protein c-kit inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Gastrointestinal stromal tumours; Systemic mastocytosis
- Phase II Haematological malignancies
- Phase I/II Solid tumours
Most Recent Events
- 02 Jun 2025 Sanofi and Blueprint Medicines enters into a agreement to acquire avapritinib
- 01 May 2025 Launched for Gastrointestinal stromal tumours (Inoperable/Unresectable, Metastatic disease, Monotherapy, In adults) in Hungary (PO) before May 2025
- 01 May 2025 Launched for Systemic mastocytosis (Second-line therapy or greater, Monotherapy, Late-stage disease, In adults) in Hungary (PO) before May 2025